Table 1.
The diagnostic value of SLNM in high-risk EC.
| Author | Year of publish | Country | Study type | Study period | Number of pts | Histology | SLN method (dye and injection site) | Surgery approach | Overall DR | BDR | PASDR | Sensitivity | NPV | FNR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Burke et al. (30) | 1996 | USA | pilot | NA | 15 | EEC(G2,G3), CC, USC | BD; subserosal, myometrium | Lpt | 67% | NA | NA | 66.70% | 87.50% | 33.30% |
| Frumovitz et al. (108) | 2007 | USA | pro | 2002-2004 | 18 | EEC(G2,G3), CC, USC | BD, Tc; Fundus | Lps | 45.00% | 5.56% | 22.22% | NA | NA | NA |
| Torne et al. (53) | 2013 | Spain | pro | 2006.03-2011.03 | 74 | EEC(G3),CC,USC,DM,CI | Tc; TUMIR | Lps | 74.30% | 14.00% | 45.40% | 92.30% | 97.70% | 7.70% |
| Perissinotti et al. (99) | 2013 | Spain | pro | 2007.06-2010.12 | 44 | EEC(G3),CC,USC,USM,DM | Tc; TUMIR | Lps | 73.00% | NA | NA | NA | NA | NA |
| Farghali et al. (100) | 2015 | Egypt | pro | 2007.05 -2011.05 | 93 | EEC(G2,G3), CC, USC | BD; subserosal, myometrium | Lpt | 73.10% | 40.86% | 0.00% | 94.40% | 98.90% | 5.88% |
| Valha et al. (109) | 2015 | Czech | pro | 2012.06-2014.02 | 18 | stage I-II, intermediate and high-risk | BD; subserosal | Lpt | 88.89% | NA | 50.00% | NA | NA | NA |
| Ehrisman et al. (101) | 2016 | USA | retro | 2012.08-2015.06 | 36 | EEC(G3),CC,USC,CSM | BD,ICG;cervical | Lps,Rb | 83.00% | 56.00% | 3.00% | 77.80% | 92.30% | 22.22% |
| Baiocchi et al. (106) | 2017 | Spain | retro | 2007.06-2017.02 | 236(75 SLN+LAD; 161 LAD) | EEC(G3),CC,USC,CSM,DM,LVSI | BD; cervical | Lps,Rb,Lpt | 85.30% | 60.00% | 1.50% | 90.90% | 95.7%, | 10.00% |
| Tanner et al.J (110) | 2017 | USA | retro | 2012.12- 2015.12 | 52 | EEC(G3),CC,USC,CSM | BD,ICG;cervical | Lps,Rb | 86.00% | 59.60% | 9.00% | 77.80% | 94.70% | 22.20% |
| Soliman, PT (103) | 2017 | USA | pro | 2013.04- 2016.05 | 101 | EEC(G3),CC,USC,CSM,DM,CI | ICG, BD, BD+Tc; cervical | Lps,Rb,Lpt | 89.00% | 58.00% | 2.00% | 95.80% | 98.20% | 5.00% |
| Touhami et al. (104). | 2017 | Canada | retro | 2010.11- 2016.11 | 128 | EEC(G3),CC,USC,CSM,undifferentiated | BD, Tc, ICG; cervical | Lps,Rb,Lpt | 89.80% | 63.20% | 5.00% | 97.43% | 98.80% | 2.56% |
| Ducie et al. (107) | 2017 | USA | retro | 2006–2013 | 120 | EEC+any grade+DM;USC, CC | BD, ICG; cervical | NA | NA | NA | NA | 96.40% | 98.90% | 3.60% |
| Buda et al. (111) | 2018 | Italy, Switzerland | retro | NA | 171 | ESMO high-intermediate and high risk | ICG, Tc+BD; cervical | NA | 98.00% | 80.1%(ICG); 65.7%(BD,Tc) | NA | 85.2%; 91.2% for algorithm | 93.4%;96% for algorithm | 14.7%;8.8% for algorithm |
| Papadia et al. (42) | 2018 | Switzerland | retro | 2012.12 - 2017.07 | 42 | EEC(G3),CC,USC,CSM,NEC | ICG; cervical | Lps | 100% | 90.50% | NA | 90%;100% for algorithm | 97%;100% for algorithm | 10%;0% for algorithm |
| Persson et al. (72) | 2019 | Sweden | pro | 2014.06-2018.05 | 257 | EEC(G3),non-EEC, DM, CI, non-diploid cell | ICG; cervical+/-reinjection | Rb | NA | 82%; 94.8% after reinjection | NA | 98%; 100% for algorithm | 99.5%;100% for algorithm | 3.7%;0% for algorithm |
| Wang et al. (105) | 2019 | China | retro | 2016.08-2018.08 | 98 | EEC(G3),CC,USC,CSM,EEC(G1,G2) +DM,CI | ICG; cervical | NA | 95.92% | 77.60% | NA | 88.2%; 90.9% for algorithm | 97.47%; 97.30% for algorithm | 11.8%; 9.1% for algorithm |
| Ye et al. (112) | 2019 | China | pro | 2016.07-2018.07 | 131 pts with 25 high-risk | EEC(G3),CC,USC,CSM,undifferentiated | ICG; cervical | Lps | 100% | 72% | NA | 20% | 83.30% | 80% |
| Angeles et al. (76) | 2020 | Spain | pro | 2006.03-2017.03 | 123 | intermediate and high-risk EC | TUMIR | NA | 70.70% | NA | NA | NA | NA | NA |
| Taskin et al. (113) | 2020 | Turkey | retro | 2017.05-2018.11 | 38 | high-risk (Mayo criteria) | ICG; cervical | Lps,Rb,Lpt | 84.21% | 68.40% | NA | 80% | 93.40% | NA |
pts, patients; SLN, sentinel lymph node; LAD, lymphadenectomy; DR, detection rate; BDR, bilateral detection rate; PAS, para-aortic SLN; NPV, negative predictive value; FNR, false negative rate; NA, not applicable; EEC, endometrioid endometrial cancer; G, grade; CC, clear cell carcinoma; USC, uterine serous carcinoma; CSM, carcinosarcoma; DM, deep myometrial invasion; CI, cervical involvement; BD, blue dye; Tc, Technetium-99; TUMIR, transvaginal ultrasound-guided myometrial injection of radiotracer; Lpt, laparotomy; Lps, laparoscopic; Rb, robotic surgery; pro, prospective; retro, retrospective.